Ensartinib after surgery for ALK-positive early lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether taking a pill called ensartinib after surgery can help prevent early stage lung cancer from coming back. It is for people whose tumors have a specific gene change called ALK and who have high-risk features.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your tumor was completely removed by surgery and is stage I lung adenocarcinoma.
- Your tumor has a specific genetic change called ALK.
- You have not had other cancer treatments (like chemotherapy or radiation) for this lung cancer.
- You have at least one high-risk feature (like a poorly differentiated tumor or blood vessel invasion).
- You can start taking the study pill within 4 to 8 weeks after surgery.
- Your blood counts and organ function (liver, kidneys) are within acceptable levels.
- If you are able to become pregnant, you must have a negative pregnancy test and use reliable birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests the drug ensartinib, given before surgery, for people with ALK-positive lung cancer. Taking ensartinib first might shrink the tumor and make surgery more effective.
This trial tests a pill called ensartinib after you finish chemotherapy and radiation for stage III ALK-positive lung cancer. It may help keep the cancer from coming back.
This study looks at whether giving a targeted therapy pill (lorlatinib) before surgery can help shrink ALK-positive lung cancer and improve outcomes. It also aims to understand why some tumors may not respond to this treatment.
This trial tests whether taking ensartinib after surgery can lower the chance of lung cancer coming back in people whose tumors have a specific genetic change called ALK. The study uses a blood test called MRD to guide treatment.
This trial studies whether taking ensartinib (a targeted pill) after lung cancer surgery can lower the chance the cancer comes back. It is for people with ALK-positive non-small cell lung cancer (NSCLC) whose cancer has been fully removed and who have recovered from treatment.
This trial tests a pill called ensartinib, given before surgery to people with ALK-positive lung cancer. The goal is to see if it helps shrink the tumor and improve the chance of successful surgery.
Hear when a new ALK trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.